生物制剂在类风湿关节炎中的应用与进展

被引：49

作者：

郑文洁

曾小峰

机构：

[1] 中国医学科学院北京协和医学院北京协和医院风湿免疫科,风湿免疫病学教育部重点实验室

来源：

临床药物治疗杂志 | 2014年 / 12卷 / 04期

关键词：

生物制剂; 类风湿关节炎;

D O I：

暂无

中图分类号：

R593.22 [类风湿性关节炎];

学科分类号：

100201 [内科学];

摘要：

目的:介绍生物制剂在类风湿关节炎(rheumatoid arthritis,RA)中的应用及其最新研究进展。方法:根据近年来的相关文献和指南进行综述,对生物制剂在治疗RA中的作用机制、临床疗效和安全性等方面进行综述。结果和结论:生物制剂是一类安全、有效的药物,在控制风湿病情和改善生活质量方面发挥了重要作用,具有良好的临床应用前景。

引用

页码：1 / 7

页数：7

共 7 条

[1]

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial [J].

Gabay, Cem ;

Emery, Paul ;

van Vollenhoven, Ronald ;

Dikranian, Ara ;

Alten, Rieke ;

Pavelka, Karel ;

Klearman, Micki ;

Musselman, David ;

Agarwal, Sunil ;

Green, Jennifer ;

Kavanaugh, Arthur .

LANCET, 2013, 381 (9877) :1541-1550

[2]

American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis [J].

Hahn, Bevra H. ;

McMahon, Maureen A. ;

Wilkinson, Alan ;

Wallace, W. Dean ;

Daikh, David I. ;

Fitzgerald, John D. ;

Karpouzas, George A. ;

Merrill, Joan T. ;

Wallace, Daniel J. ;

Yazdany, Jinoos ;

Ramsey-Goldman, Rosalind ;

Singh, Karandeep ;

Khalighi, Mazdak ;

Choi, Soo-In ;

Gogia, Maneesh ;

Kafaja, Suzanne ;

Kamgar, Mohammad ;

Lau, Christine ;

Martin, William J. ;

Parikh, Sefali ;

Peng, Justin ;

Rastogi, Anjay ;

Chen, Weiling ;

Grossman, Jennifer M. .

ARTHRITIS CARE & RESEARCH, 2012, 64 (06) :797-808

[3]

2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis [J].

Singh, Jasvinder A. ;

Furst, Daniel E. ;

Bharat, Aseem ;

Curtis, Jeffrey R. ;

Kavanaugh, Arthur F. ;

Kremer, Joel M. ;

Moreland, Larry W. ;

O'Dell, James ;

Winthrop, Kevin L. ;

Beukelman, Timothy ;

Bridges, S. Louis, Jr. ;

Chatham, W. Winn ;

Paulus, Harold E. ;

Suarez-Almazor, Maria ;

Bombardier, Claire ;

Dougados, Maxime ;

Khanna, Dinesh ;

King, Charles M. ;

Leong, Amye L. ;

Matteson, Eric L. ;

Schousboe, John T. ;

Moynihan, Eileen ;

Kolba, Karen S. ;

Jain, Archana ;

Volkmann, Elizabeth R. ;

Agrawal, Harsh ;

Bae, Sangmee ;

Mudano, Amy S. ;

Patkar, Nivedita M. ;

Saag, Kenneth G. .

ARTHRITIS CARE & RESEARCH, 2012, 64 (05) :625-639

[4]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis [J].

Jamal, Shahin ;

Patra, Kaushik ;

Keystone, Edward C. .

CLINICAL RHEUMATOLOGY, 2009, 28 (04) :413-419

[5]

Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study [J].

Genovese, Mark C. ;

McKay, James D. ;

Nasonov, Evgeny L. ;

Mysler, Eduardo F. ;

da Silva, Nilzio A. ;

Alecock, Emma ;

Woodworth, Thasia ;

Gomez-Rein, Juan J. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (10) :2968-2980

[6]

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].

Emery, Paul ;

Breedveld, Ferdinand C. ;

Hall, Stephen ;

Durez, Patrick ;

Chang, David J. ;

Robertson, Deborah ;

Singh, Amitabh ;

Pedersen, Ronald D. ;

Koenig, Andrew S. ;

Freundlich, Bruce .

LANCET, 2008, 372 (9636) :375-382

[7]

Adalimumab; a fully human anti–tumor necrosis factor α monoclonal antibody; for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial.[J].Michael E. Weinblatt;Edward C. Keystone;Daniel E. Furst;Larry W. Moreland;Michael H. Weisman;Charles A. Birbara;Leah A. Teoh;Steven A. Fischkoff;Elliot K. Chartash.Arthritis & Rheumatism.2003, 1

← 1 →